A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib.

ABSTRACT:

SUBMITTER: Desai J 

PROVIDER: S-EPMC11694331 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature